Home/Pipeline/Flucelvax Quadrivalent (cell-based)

Flucelvax Quadrivalent (cell-based)

Seasonal Influenza

MarketedLifecycle Management

Key Facts

Indication

Seasonal Influenza

Phase

Marketed

Status

Lifecycle Management

Company

CSL Seqirus

About CSL Seqirus

CSL Seqirus is a mission-driven global leader in influenza vaccines, leveraging its position within the CSL Limited ecosystem to advance public health. Its strategy is built on a diversified technology platform, a broad product portfolio, and a robust global manufacturing footprint. The company plays a pivotal role in seasonal flu prevention and is a key partner to governments worldwide for pandemic response, underpinned by continuous R&D and strategic in-licensing.

View full company profile

Therapeutic Areas

Infectious Disease Pandemic Preparedness

Other Seasonal Influenza Drugs

Drug	Company	Phase	Status
MF59-Adjuvanted Seasonal Vaccines	CSL Seqirus	Marketed	Lifecycle Management
Flublok Quadrivalent (recombinant)	CSL Seqirus	Marketed	Lifecycle Management
mRNA-based Influenza Vaccine	Sanofi	Phase 3	Active
mRNA-1010/1011	Moderna	Phase 3	Active
Standalone Seasonal Influenza Vaccine	Novavax	Phase 3	Active
LUNAR®-FLU (ARCT-2138)	Arcturus Therapeutics	Phase 1	Status Unknown
Oral Influenza Vaccine	Vaxart	Phase 2	Active